논문검색
Author Jae-Sook Ahn, M.D.1, Sang-Hee Cho, M.D.1, Ok-Ki Kim, M.D.1, Joon-Kyoo Lee, M.D.2, Deok-Hwan Yang, M.D.1, Yeo-Kyeoung Kim, M.D.1, Je-Jung Lee, M.D.1, Sang-Chul Lim, M.D.2, Hyeoung-Joon Kim, M.D.1, Woong-Ki Chung, M.D.3 and Ik-Joo Chung, M.D.1
Place of duty Departments of 1Hemato-Oncology, 2Otorhinolaryngology-Head and Neck Surgery and 3Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea
Title The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer
Publicationinfo Cancer Res Treat 2007 Sep; 039(03): 93-98.
Key_word Head and neck neoplasms, Radiotherapy, Docetaxel, Combination chemotherapy
Full-Text
Abstract Purpose: This study was performed to determine the feasibility and safety of the use of induction chemotherapy combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiation therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Materials and Methods: The patients, that were initially not treated for locally advanced SCCHN, underwent three cycles of induction chemotherapy every 3 weeks at a dose of 70 mg/m2 docetaxel D1, 75 mg/m2 cisplatin D1, 1000 mg/m2 5-FU D1-4, and subsequently received concurrent chemoradiation therapy. Results: Forty-nine patients were enrolled in this study and forty-three of the patients completed the treatment. The median duration of follow-up was 18 months (range, 6∼39 months). All of the patients had stage III (26.5%) or IV (73.5%) squamous cell carcinoma. After sequential therapy, a complete response and partial response was seen in 28 (65.2%) and 13 (30.2%) patients, respectively. The overall response rate was 95.4%. Overall survival and progression-free survival (PFS) at 2 years were 88.7% and 69.7%, respectively. Grade 3∼4 neutropenia occurred in 42.2% of the patients and grade 4 thrombocytopenia in 1 cycle (0.7%). Two patients (4.1%) died during the induction chemotherapy due to pneumonia and a subdural hemorrhage, respectively. The group of patients over 65 years of age showed a significant lower dose intensity than that of patients under 65 years of age, but PFS was not significantly different between two groups (p=0.105). Conclusion: TPF induction chemotherapy followed by concurrent chemoradiotherapy showed a high level of CR and moderate treatment-induced toxicity. Adequate dose modification in elderly patients should be considered to maintain efficacy and avoid treatment-related toxicity. (Cancer Res Treat. 2007;39:93-98)
출판정보 대한암학회지 2007 Sep; 039(03): 93-98.